Novel OMV vaccine platform for quick response to Disease X

Abera的疫苗平台能够通过共价偶联在外膜泡(OMV)上展示多种抗原。这些OMV纳米颗粒具有固有的佐剂活性，可诱导强大的体液和细胞免疫反应。这个项目的主要目标是加快开发一个快速反应的平台，以开发针对X疾病暴发的疫苗。这些疫苗的特点是非常有效、快速的开发过程、成本效益高的生产、不需要冷链的简化物流以及疾病传播的快速中断。我们的目标是建立一个生产程序来储存OMV，使它们在大流行期间能够迅速与抗原结合。这一办法将加快疫苗开发，确保公平获得疫苗，特别是在低中等收入国家和官方发展援助国家。利用直截了当和强大的技术，生产将具有成本效益，并可以轻松地在全球地区转移。值得注意的是，这些疫苗与无针鼻腔给药的兼容性在抗击空气传播疾病爆发方面提供了独特的优势，在这种情况下，遏制传播至关重要。即使在高温下，OMVS也表现出固有的稳定性。为了消除冷链储存和分发的需要，进一步增强稳定性和改善疫苗的可及性，我们打算实施冷冻干燥。我们的计划包括以适当的工艺规模生产相关批次的OMV，以证明库存的一致性和稳定性。此外，我们将开发一套分析包来评估延长储存条件下成批抗原偶联的容量和一致性。此外，我们将评估适当的免疫反应的诱导。此外，我们计划建立一个监管战略，在大流行爆发的情况下基于该平台快速批准新疫苗。总而言之，阿贝拉的疫苗平台及其基于OMV的技术有望彻底改变疫苗开发。通过建立OMV库存的生产程序并确保其一致性和稳定性，我们可以迅速应对疫情，同时还能够广泛和公平地获得疫苗，即使在资源有限的情况下也是如此。通过这些努力，我们的目标是建立一个全面的监管框架，在大流行期间加快新疫苗的审批。

Abera's vaccine platform enables display of multiple antigens on Outer Membrane Vesicles (OMVs) through covalent-based coupling. These OMV nanoparticles possess inherent adjuvant activity, which elicits robust humoral and cellular immune responses. The primary objective of this project is to expedite the development of a rapid responsive platform for development of vaccines against outbreaks of Disease X. These vaccines are characterized by their exceptional efficiency, rapid development process, cost-effective production, streamlined logistics without the need for cold chain, and swift interruption of disease transmission.Our aim is to establish a production process to stockpile OMVs, enabling their prompt coupling to antigens during times of pandemics. This approach will accelerate vaccine development and ensure equitable access to vaccines, particularly in LMICs and ODA countries. Leveraging straightforward and robust technologies, production will be cost-effective and easily transferable across global regions. Notably, the compatibility of these vaccines with needle-free intranasal administration offers a unique advantage in combatting airborne disease outbreaks, where curbing transmission is of paramount importance. OMVs exhibit inherent stability, even under elevated temperatures. To further enhance stability and improve vaccine accessibility by eliminating the need for cold chain storage and distribution, we intend to implement lyophilisation.Our plan involves producing relevant batches of OMVs at a suitable process scale to demonstrate consistency and stability in stockpiles. Additionally, we will develop an analytical package to assess the capacity and consistency of antigen coupling in batches subjected to extended storage. Furthermore, we will evaluate the induction of appropriate immune responses. Moreover, we plan to establish a regulatory strategy for fast approval of a new vaccine based on the platform in case of a pandemic outbreak.In conclusion, Abera's vaccine platform, with its OMV-based technology, promises to revolutionize vaccine development. By establishing a production process for OMV stockpiles and ensuring their consistency and stability, we can swiftly respond to outbreaks, while also enabling widespread and equitable access to vaccines, even in resource-constrained settings. Through these efforts, we aim to create a comprehensive regulatory framework that expedites the approval of new vaccines during pandemics.